Seoul: Celltrion Inc., a major South Korean biopharmaceutical company, announced the launch of its biosimilar drug Stoboclo-Osenvelt across major European markets. This follows the product's initial rollout in the United States in July.
According to Yonhap News Agency, Stoboclo-Osenvelt received sales approval from the European Commission in February. It is a biosimilar referencing U.S. biotech firm Amgen's osteoporosis treatment Prolia-Xgeva. The drug is now available in Germany, Spain, France, and Portugal, with Celltrion aiming to introduce it in additional European countries to expand its footprint in the bone disease treatment sector.
The global market for the reference drug Prolia-Xgeva was valued at 9.2 trillion won (approximately US$6.59 billion) last year. Celltrion has been actively expanding its global biosimilar portfolio, growing the number of approved products from six to 11. The company has set a target to commercialize 18 biosimilars by 2030 and increase that number to 41 by 2038.
In addition to its biosimilars, Celltrion's only original drug, Zymfentra, is currently sold in the U.S. for treating autoimmune diseases. The same product is marketed as Remsima SC in Europe and other regions.